Nomura Asset Management International’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$56.8M Buy
2,208,263
+2,093,739
+1,828% +$43M 0.09% 316
2026
Q1
$2.2M Buy
114,524
+7,031
+7% +$140K ﹤0.01% 949
2025
Q4
$1.77M Buy
+107,493
New +$1.81M ﹤0.01% 1014

Other funds holding DNLI

Nomura Asset Management International's DNLI Position: Q2 2026 in Review

Nomura Asset Management International increased its Denali Therapeutics (DNLI) stake by 1,828% in Q2 2026, buying an estimated $43M and bringing the position to 2,208,263 shares worth $56.8M. The position accounts for 0.09% of the portfolio, ranked #316.

Nomura Asset Management International first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Nomura Asset Management International held 2,208,263 shares of Denali Therapeutics worth $56.8M as of Q2 2026.
  • Nomura Asset Management International bought 2,093,739 Denali Therapeutics shares in Q2 2026, an estimated $43M.
  • Denali Therapeutics made up 0.09% of Nomura Asset Management International's portfolio in Q2 2026, its #316 holding.
  • Nomura Asset Management International first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.